| Revue: | Annals of hepatology |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000391058 |
| ISSN: | 1665-2681 |
| Autores: | Pellicelli, Adriano M1 D’Ambrosio, Cecilia1 Dessanti, Maria L2 Villani, Roberto1 Fondacaro, Lucia1 Miglioresi, Lucia1 Grillo, Lucia R1 Andreoli, Arnaldo1 |
| Instituciones: | 1Azienda Ospedaliera San Camillo Forlanini, Roma, Lazio. Italia 2Istituti Fisoterapici Ospedalieri, Dipartimento di Hematologia, Roma, Lazio. Italia |
| Año: | 2015 |
| Periodo: | Sep-Oct |
| Volumen: | 14 |
| Número: | 5 |
| Paginación: | 756-761 |
| País: | México |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Caso clínico |
| Resumen en inglés | Rituximab is a chimeric anti-CD20 monoclonal antibody that is a widely used for the treatment of B cells non-Hodgkin lymphoma. The use of chemotherapy regimens containing rituximab in HCV-positive patients with non-Hodgkin lymphoma has been associated with liver dysfunction, but no cases of cholestatic hepatitis C were described. To our knowledge, this is the first case of cholestatic hepatitis C in an HCV-positive patient with diffuse large B-cell lymphoma describes in the literature. We discuss the pathogenetic mechanisms underlying this severe form of hepatitis and describe its evolution after antiviral treatment |
| Disciplinas: | Medicina |
| Palabras clave: | Gastroenterología, Oncología, Inmunología, Daño hepático, Inmunosupresión, Rituximab, Hepatitis C |
| Keyword: | Medicine, Gastroenterology, Oncology, Immunology, Liver damage, Immunosuppression, Rituximab, Hepatitis C |
| Texte intégral: | Texto completo (Ver PDF) |
